New Publication by A. Dityatev
The CBBS congratulates Alexander Dityatevs group, located at the German Center for Neurodegenerative Diseases (DZNE), on their latest publication in the Journal of Clinical Investigation.
The important study shows that a one-week treatment with a new inhibitor of matrix metalloproteinases can suppress epileptogenesis in a mouse model of the status epilepticus. Accure Therapeutics is bringing this drug into clinical trials - expected in 2022 - as a result of a collaboration between several academic groups and a biotech company funded by EU ITN ECMED.
